BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18068534)

  • 1. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
    Hélias C; Struski S; Gervais C; Leymarie V; Mauvieux L; Herbrecht R; Lessard M
    Cancer Genet Cytogenet; 2008 Jan; 180(1):51-5. PubMed ID: 18068534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.
    Italiano A; Attias R; Aurias A; Pérot G; Burel-Vandenbos F; Otto J; Venissac N; Pedeutour F
    Cancer Genet Cytogenet; 2006 Jun; 167(2):122-30. PubMed ID: 16737911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
    Roche-Lestienne C; Andrieux J
    Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
    Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
    Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karyotype and molecular cytogenetic studies in polycythemia vera.
    Andrieux JL; Demory JL
    Curr Hematol Rep; 2005 May; 4(3):224-9. PubMed ID: 15865876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
    Schoch C; Haferlach T; Bursch S; Gerstner D; Schnittger S; Dugas M; Kern W; Löffler H; Hiddemann W
    Genes Chromosomes Cancer; 2002 Sep; 35(1):20-9. PubMed ID: 12203786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
    Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
    Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
    Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K
    Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
    Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P
    Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of 9p in the pathogenesis of polycythemia vera.
    Chen Z; Notohamiprodjo M; Guan XY; Paietta E; Blackwell S; Stout K; Turner A; Richkind K; Trent JM; Lamb A; Sandberg AA
    Genes Chromosomes Cancer; 1998 Aug; 22(4):321-4. PubMed ID: 9669670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.